Literature DB >> 22554417

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Margaret Rosenfeld1, Julia Emerson, Sharon McNamara, Valeria Thompson, Bonnie W Ramsey, Wayne Morgan, Ronald L Gibson.   

Abstract

BACKGROUND: Risk factors for initial Pseudomonas aeruginosa (Pa) acquisition, particularly environmental exposures, are poorly understood. We aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations.
METHODS: The study cohort included all participants in the U.S. EPIC Observational Study who had no prior Pa-positive respiratory cultures (N=889). Cox proportional hazard models were used to test the effects of factors on age at first Pa-positive respiratory culture.
RESULTS: Cystic fibrosis (CF) genotype functional class had an important effect on age at initial Pa acquisition (hazard ratio (HR) comparing minimal to residual CFTR function 2.87 (95% CI 1.88, 4.39)). None of the modifiable risk factors evaluated, including cigarette smoke, hot tub use, breastfeeding, or daycare, was associated with age at Pa acquisition. Similarly, newborn screening was not associated with age at Pa acquisition (HR 0.85, 95% CI 0.66, 1.09). Key associations were validated in a CF Foundation National Patient Registry replication cohort.
CONCLUSIONS: Given the ubiquitous presence of Pa in the environment, it may be that many imposed lifestyle changes will have less impact on age at initial Pa acquisition than genetic determinants.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554417      PMCID: PMC4786375          DOI: 10.1016/j.jcf.2012.04.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  38 in total

1.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

2.  Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Kelli Joubran; George Retsch-Bogart; Gavin R Graff; Hector H Gutierrez; Jamshed F Kanga; Thomas Lahiri; Blake Noyes; Bonnie Ramsey; Clement L Ren; Michael Schechter; Wayne Morgan; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2010-09

3.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

4.  Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa.

Authors:  Milan Bajmoczi; Mihaela Gadjeva; Seth L Alper; Gerald B Pier; David E Golan
Journal:  Am J Physiol Cell Physiol       Date:  2009-04-22       Impact factor: 4.249

5.  Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Authors:  Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin
Journal:  Pediatr Pulmonol       Date:  2008-05

Review 6.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Am J Infect Control       Date:  2003-05       Impact factor: 2.918

7.  Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis.

Authors:  C Goubau; M Wilschanski; V Skalická; P Lebecque; K W Southern; I Sermet; A Munck; N Derichs; P G Middleton; L Hjelte; R Padoan; M Vasar; K De Boeck
Journal:  Thorax       Date:  2009-03-23       Impact factor: 9.139

8.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Authors:  Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey
Journal:  Contemp Clin Trials       Date:  2009-01-15       Impact factor: 2.226

9.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

10.  Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis.

Authors:  P Kubesch; T Dörk; U Wulbrand; N Kälin; T Neumann; B Wulf; H Geerlings; H Weissbrodt; H von der Hardt; B Tümmler
Journal:  Lancet       Date:  1993-01-23       Impact factor: 79.321

View more
  23 in total

1.  Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.

Authors:  Clélia Buchs; Marie-Laure Dalphin; Stéphane Sanchez; Marie Perceval; Laurianne Coutier; Catherine Mainguy; Behrouz Kassaï-Koupaï; Philippe Reix
Journal:  Eur J Pediatr       Date:  2017-05-16       Impact factor: 3.183

2.  Cystic fibrosis transmembrane conductance regulator and pseudomonas.

Authors:  Edith T Zemanick; Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

3.  Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study.

Authors:  Rocio Rivas Caldas; Florence Le Gall; Krista Revert; Gilles Rault; Michèle Virmaux; Stephanie Gouriou; Geneviève Héry-Arnaud; Georges Barbier; Sylvie Boisramé
Journal:  J Clin Microbiol       Date:  2015-04-08       Impact factor: 5.948

4.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08

Review 5.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

6.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

Review 7.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

8.  Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States.

Authors:  Meghan E McGarry; Chiung-Yu Huang; Dennis W Nielson; Ngoc P Ly
Journal:  J Cyst Fibros       Date:  2020-11-05       Impact factor: 5.482

9.  Citizen-science based study of the oral microbiome in Cystic fibrosis and matched controls reveals major differences in diversity and abundance of bacterial and fungal species.

Authors:  Jesse R Willis; Ester Saus; Susana Iraola-Guzmán; Elena Cabello-Yeves; Ewa Ksiezopolska; Luca Cozzuto; Luis A Bejarano; Nuria Andreu-Somavilla; Miriam Alloza-Trabado; Andrea Blanco; Anna Puig-Sola; Elisabetta Broglio; Carlo Carolis; Julia Ponomarenko; Jochen Hecht; Toni Gabaldón
Journal:  J Oral Microbiol       Date:  2021-05-17       Impact factor: 5.474

10.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.